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Background: Surgery first (SF) versus neoadjuvant approach (NAT) to management of potentially resectable 
pancreatic ductal adenocarcinoma (PDAC) is controversial. This study is unique in utilizing institutional data to offer 
Markov decision-analysis of overall treatment pathways for resectable PDAC (RPC). Methods: An advanced Markov 
decision analysis model was constructed and populated with data from a retrospective institutional database. 
Patients presenting with resectable PDAC from 2008-2012 were included in the SF arm. Those presenting with 
resectable PDAC from 2012-2016 and treated within NAT pathway populated the NAT arm. Model uncertainties were 
tested with one and two-way deterministic sensitivity analysis and probabilistic Monte Carlo sensitivity analysis set to 
1000 cycles with variables altered between highest and lowest observed values. Results: NAT pathway gave an 
additional 0.58 QALMs (22.43 vs. 21.85 QALMs). Monte Carlo analysis reported indifference between treatment 
strategies. One-way deterministic sensitivity analysis showed that probability of resection in the SF pathway must be 
greater than 0.82, or below 0.72 in NAT pathway, and probability of receiving adjuvant therapy above 0.6 to alter 
pathway superiority. Two-way deterministic sensitivity analysis demonstrated treatment superiority depended on 
resection rate in each pathway and receiving adjuvant therapy in SF pathway. Markov cohort analysis demonstrated 
superiority of neoadjuvant pathway (Table 2). Conclusions: Optimal treatment pathway remains debatable on an 









The aim of this study is to create a Markov decision analysis model based on a single institution database to compare 
SF versus NAT pathways for treatment of RPC. Approaches were assessed on an intention-to-treat basis and Markov 
Cohort analysis of treatment received.  
Probabilities of interventions, clinical outcomes, and survival in both SF and NAT cohorts were calculated from the 
West of Scotland Pancreatic Unit prospective database which recorded data for a cohort of 201 sequential patients 
diagnosed with RPC and fit for surgery at initial staging. All patients underwent surgery in the West of Scotland 
Pancreatic Unit. SF pathway was exclusively performed from January 2008 to July 2012. From 1st August 2012-30th 
December 2015 100 patients with non-metastatic pancreatic ductal adenocarcinoma (PDAC) were treated in NAT 
pathway. For this model only those patients with resectable disease on completion of initial staging prior to 
commencing NAT were included (n=56). Borderline and locally advanced PC were determined according to AHPBA/
SSO/SSAT guidelines1. From August 2012 working backwards, 100 sequential patients in SF pathway who had 
resectable PC, and were deemed fit for surgery based on performance status score and CPET populated the SF arm 
of the model.  No patients were lost to follow-up.    
Neoadjuvant regime was FOLFIRINOX unless patients had: poor performance status, were aged over 70 years, or 
FOLFIRINOX was poorly tolerated, whereby they received Gemcitabine+Capcitabine (GEMCAP).   
Ethical approval for data collection was granted by the West of Scotland Local Research Ethics Committee.  
A Markov cohort decision analysis model was constructed using TreeAge Pro 2017 (TreeAge Software Ins., 
Williamstown, MA). The base case, surgery first followed by adjuvant therapy, was compared to neoadjuvant therapy 
followed by re-staging and, if appropriate, by surgical resection.  
Transition nodes were based on outcomes of response to neoadjuvant therapy on repeat CT scan (for the 
neoadjuvant cohort only), operative intervention and outcome, post-operative complication, and receipt of adjuvant 
therapy based on postoperative complication occurrence. Results were adjusted based in quality-of-life indicies for 
surgery, chemotherapy and/or radiotherapy, and no treatment were taken from published literature (table 1).  
Each cycle length was one month with a total number of 60 cycles. Patients cycled through the model until death or 
with a total follow-up time of 60 months for those still alive at model completion. For the Markov cohort analysis 
survival time was calculated from median survival time of each cohort based on: intervention, post-operative 
complication and neoadjuvant/ adjuvant therapy. Markov survival states included: disease free survival, alive with 
disease and dead.  
In intention-to-treat analysis of the treatment 
pathways, NAT gave an additional 0.58 QALMs 
(22.43 versus 21.85 QALMs). The results of 
Markov Cohort analysis (Table 2) demonstrated 
superiority of NAT pathway. One-way 
deterministic sensitivity analysis showed that 
probability of resection and probability of receiving 
adjuvant therapy in SF pathway altered pathway 
superiority (Figures1-3). Two-way deterministic 
sensitivity analysis demonstrated treatment 
superiority depended on resection rate in each 
pathway (Figures 4&5) and receiving adjuvant 
therapy in SF pathway (Figure 6). Probabilistic 
Monte Carlo sensitivity analysis set to 1000 
cycles reported indifference between pathways 
when indifference threshold was set greater than 
0.5 months.  
 
Figure 2: One-way sensitivity analysis showing threshold of resection in surgery first 
cohort that must be achieved to make SF optimal strategy in overall raking analysis. Y axis 





Figure 1: One-way sensitivity analysis showing threshold of probability of resection in 
neoadjuvant pathway that must be reached to maintain optimal strategy in ranking analysis. Y 
axis shows expected quality-adjusted survival, x axis shows probability of resection in NAT 
pathway. 
Table 1: utilities for quality adjusted life month (QALM) survival from literatire 2-7 
Figure 3: One-way sensitivity analysis showing threshold probability of receiving adjuvant therapy 
that must be achieved to make SF optimal strategy in overall raking analysis. Y axis shows 
expected quality-adjusted survival, x axis shows probability of receiving adjuvant therapy post 
resection in SF pathway. 
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Figure 4: Two-way sensitivity analysis altering rate of resection following NAT and a) months to disease reoccurrence and b) months to death in neoadjuvant followed by resection group. Blue area depicts where 






Figure 5: Two-way sensitivity analysis altering rate of resection in SF pathway and months 
to death. Blue area depicts where neoadjuvant approach givens optimal quality adjusted 







Figure 6: Two-way sensitivity analysis altering rate of adjuvant therapy following resection in 
SF pathway and months to death. Y-axis shows time in months. X-axis shows probability of 
receiving adjuvant therapy post resection. Blue area depicts where neoadjuvant approach 
givens optimal quality adjusted survival.  
In conclusion the Markov decision analysis showed superiority of survival time, and quality adjusted survival time, 
with NAT pathway when all treatment modalities (i.e. surgery and chemotherapy) were completed.  
 
This finding in the context of an absence of conclusive superiority of one pathway over another on an intention-to-
treat basis highlights two important directions for future research based on Markov decision analysis:  
 
1)  cost-effectiveness analysis of neoadjuvant versus upfront surgery 
2)  exploring methods of predictive statistical modeling to identify patients who are more likely to receive and benefit 
from differing treatment modalities.  
 
By moving research in this direction it is hoped that we can find a path from ambiguity to precision medicine with 
associated benefit to patients and resource utilisation.  
